The rising landscape of India’s pharmaceuticals is witnessing significant interest on Retatrutide, a novel dual GIP and GLP-1 receptor exhibiting potential for obesity treatment . This peptide is generating considerable buzz within the medical community, particularly as local companies pursue distri